Skip to main content
  • EuroPCR: Magmaris Resorbable Magnesium Scaffold Confirms High Safety Profile at 3 Years With BIOSOLVE-IV Data

    Two poster sessions at EuroPCR focus on Magmaris’ safety profile for the first cohort after three years and the full cohort subgroup analysis at one-year follow-up

    Two posters presented at the EuroPCR provided new insights into the safety profile of BIOTRONIK's Magmaris® Resorbable Magnesium Scaffold (RMS). BIOSOLVE-IV study investigator Prof. Dr. Jan Torzewski, Cardiovascular Center Oberallgäu-Kempten, Germany, presented novel long-term data for the first cohort of the study. The evaluation of 1075 patients across 23 countries confirmed a good safety profile for the Magmaris RMS up to 36 months in a real-world setting. At 8.2 %, the target lesion failure rate (TLF) at 36 months1 is comparable to the low TLF rates of a contemporary DES such as Orsiro with 8.2% and Xience with 13.6% in the BIOFLOW-V trial2 over the same time period.  

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details